We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP
RNS Number : 9441F
Verona Pharma PLC
23 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) -------------------------------------------------- 1. Identity of the issuer or Verona Pharma plc the underlying issuer of existing shares to which voting rights are attached: (ii) ------------------------------------------------------------- ----------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): -------------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights ---------------------------------------------------------------- -------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ---------------------------------------------------------------- -------------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ---------------------------------------------------------------- -------------------------------- An event changing the breakdown of voting rights ---------------------------------------------------------------- -------------------------------- Other (please X specify): Change to notifiable interest following share issue. --------------------------------------------------------- ----- -------------------------------- 3. Full name of person(s) Abingworth LLP subject to the Abingworth Bioventures VI notification obligation: LP (iii) ----------------------------------------------------------- ------------------------------------- 4. Full name of shareholder(s) State Street (Nominees) Limited (if different from 3.):(iv) (as nominee for Abingworth Bioventures V LP) ----------------------------------------------------------- ------------------------------------- 5. Date of the transaction 19 May 2017 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- ------------------------------------- 6. Date on which issuer 22 May 2017 notified: ----------------------------------------------------------- ------------------------------------- 7. Threshold(s) that is/are Downward crossing of the 7%, crossed or threshold reached: (vi, vii) ----------------------------------------------------------- ------------------------------------- 8. Notified details: Abingworth LLP ---------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE -------------- -------------------------------- -------------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights -------------- --------------- --------------- ---------------------- --------------------- --------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) -------------- ----------- ----------- ---------------------- --------- ---------- ------------ ------------- Verona Pharma plc 3,510,553 3,510,553 3,510,553 0 3,510,553 0 3.36% GB00B06GSH43 5p Ords --------------- --------------- ------------ ------------------- ---------- -------------- ----------- Verona Pharma plc US9250501064 ADSs 3,705,000 3,705,000 3,705,000 0 3,705,000 0 3.54% -------------- --------------- --------------- ------------ ------------------- ---------- -------------- ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------------- Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion rights that rights (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ------------------ ------------- --------------------------------------- ----------------------- ----------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) ---------------- ------------- ------------- ------------------------ ----------------------- ------------------------- Nominal Delta ---------------- ------------- ------------- ------------------------ ----------------------- -------------- --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights -------------------------------------------------- ------------------------------------------------------------------------ 7,215,553 6.90% -------------------------------------------------- ------------------------------------------------------------------------ 8. Notified details: Abingworth Bioventures VI LP ----------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ----------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE -------------- -------------------------------------------- --------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights -------------- ----------------- ------------------------- ------------ ----------------------- ------------------------ Direct Direct Indirect Direct Indirect (xi) (xii) -------------- ----------- ----------- -------- ------------ ------------ --------- ------------ ---------- Verona Pharma plc 3,510,553 3,510,553 3,510,553 3,510,553 0 3.36% 0 GB00B06GSH43 5p Ords
--------------- ------------------------- ------------ -------------- --------- ------------ ---------- Verona Pharma plc US9250501064 ADSs 3,750,000 3,750,000 3,705,000 3,705,000 0 3.54 0 -------------- --------------- ------------------------- ------------ -------------- --------- ------------ ---------- B: Qualifying Financial Instruments ----------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ----------------------------------------------------------------------------------------------------------------------------- Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion rights that rights (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ------------------ --------------- --------------------------------------- ------------------------- -------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ----------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ----------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) ---------------- --------------- ------------- ------------------------ ------------------------- ---------------------- Nominal Delta ---------------- --------------- ------------- ------------------------ ------------------------- ---------- ---------- Total (A+B+C) ----------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------------------------------ --------------------------------------------------- 7,215,553 6.90% ------------------------------------------------------------------------ --------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ----------------------------------------------------------------------------------------------------------------------------- Abingworth Bioventures VI LP (which holds 7,215,553 shares in the company (6.90%)) is managed by Abingworth LLP. Proxy Voting: ----------------------------------------------------------------------------------------------------------------------------- 10. Name of the proxy holder: ---------------------------------------------------------------------------------------- ----------------------------------- 11. Number of voting rights proxy holder will cease to hold: ---------------------------------------------------------------------------------------- ----------------------------------- 12. Date on which proxy holder will cease to hold voting rights: ---------------------------------------------------------------------------------------- ----------------------------------- 13. Additional information: ------------------------------------------------------------------------ --------------------------------------------------- 14. Contact name: John Heard ------------------------------------------------------------------------ --------------------------------------------------- 15. Contact telephone number: 020 7534 1500 ------------------------------------------------------------------------ ---------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUGCAUPMUMW
(END) Dow Jones Newswires
May 23, 2017 03:44 ET (07:44 GMT)
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions